Eight hours of cold static storage with adenosine and lidocaine (Adenocaine) heart preservation solutions: Toward therapeutic suspended animation

Rudd, Donna; Dobson, Geoffrey P.

doi:10.1016/j.jtcvs.2011.05.023

Cited by 38 publications

(20 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many of us still hope for a magic adenosine bullet. These present data from Granfeldt et al (3) add to other promising myocardial protective effects for adenosine-related compounds both in animal models (12) and in patients (13) and should stimulate a new generation of investigators. We can be cautiously optimistic, but it is appropriate to point out that in the past 40 yrs, there have been numerous studies showing benefit with several other adenosine regulating agents (alone or in combination with hypertonic resuscitation) in various hemorrhagic shock models, but none have translated into clinical success.…”

Section: Referencesmentioning

confidence: 57%

Clinically relevant animal models needed to advance state of the art fluid resuscitation*

Haren

Proctor

2012

Critical Care Medicine

View full text Add to dashboard Cite

Section: Referencesmentioning

confidence: 57%

Clinically relevant animal models needed to advance state of the art fluid resuscitation*

Haren

Proctor

2012

Critical Care Medicine

View full text Add to dashboard Cite

“…Its role in heart preservation is currently being investigated. Results from Dobson et al showed favourable recovery of cardiac parameters after six hours of cold storage in AL solution [67,68].…”

Section: Organ Preservationmentioning

confidence: 99%

Primary Graft Dysfunction After Heart Transplantation

et al. 2014

View full text Add to dashboard Cite

Primary graft dysfunction (PGD) is a lifethreatening complication of heart transplantation that presents as left, right, or biventricular dysfunction occurring within the first 24 hours of transplant surgery for which there is no identifiable secondary cause. Myocardial injury caused by acute catecholamine toxicity and the release of multiple proinflammatory mediators in the donor, followed by ischaemiareperfusion injury sustained during retrieval, have been considered the predominant pathogenetic processes leading to PGD. Donor, recipient, and procedural factors contribute to the development and severity of the clinical syndrome. The changing donor and recipient characteristics over the last two decades, particularly the increasing donor and recipient age, have led to heightened risk of PGD. PGD is graded from mild to severe depending on the extent of circulatory support that is required to maintain haemodynamic stability and vital organ function. While advances in acute mechanical support devices have improved the outlook for patients with PGD, the rate of mortality remains high for those with severe PGD, reaching 40 %. Potential approaches to preventing or minimising the severity of PGD include optimising donor management, donor heart preservation, and donor/recipient matching.

show abstract

“…Attending to cardiac transplantation, preservation fluids also play a pivotal role in graft survival. A solution consisting of melatonin (100 mmol/L), adenosine (400 μmol/L), lidocaine (1000 μmol/L), and insulin (0.01 IU/mL) was compared with adenosine-lidocaine cardioplegia with low Ca 2+ /high Mg 2+ concentration levels, HTK solution, and Celsior solution (Rudd & Dobson 2011). The authors observed a higher recovery of aortic flow and coronary flow by using the melatonin preservation solution compared with other treatments.…”

Section: Preservation Solutionsmentioning

confidence: 99%

Potential benefits of melatonin in organ transplantation: a review

Esteban‐Zubero

García-Gil

López-Pingarrón

et al. 2016

Journal of Endocrinology

View full text Add to dashboard Cite

Organ transplantation is a useful therapeutic tool for patients with end-stage organ failure; however, graft rejection is a major obstacle in terms of a successful treatment. Rejection is usually a consequence of a complex immunological and nonimmunological antigen-independent cascade of events, including free radical-mediated ischemia-reperfusion injury (IRI). To reduce the frequency of this outcome, continuing improvements in the efficacy of antirejection drugs are a top priority to enhance the long-term survival of transplant recipients. Melatonin (N-acetyl-5-methoxytryptamine) is a powerful antioxidant and ant-inflammatory agent synthesized from the essential amino acidl-tryptophan; it is produced by the pineal gland as well as by many other organs including ovary, testes, bone marrow, gut, placenta, and liver. Melatonin has proven to be a potentially useful therapeutic tool in the reduction of graft rejection. Its benefits are based on its direct actions as a free radical scavenger as well as its indirect antioxidative actions in the stimulation of the cellular antioxidant defense system. Moreover, it has significant anti-inflammatory activity. Melatonin has been found to improve the beneficial effects of preservation fluids when they are enriched with the indoleamine. This article reviews the experimental evidence that melatonin is useful in reducing graft failure, especially in cardiac, bone, otolaryngology, ovarian, testicular, lung, pancreas, kidney, and liver transplantation.

show abstract

Eight hours of cold static storage with adenosine and lidocaine (Adenocaine) heart preservation solutions: Toward therapeutic suspended animation

Cited by 38 publications

References 40 publications

Clinically relevant animal models needed to advance state of the art fluid resuscitation*

Clinically relevant animal models needed to advance state of the art fluid resuscitation*

Primary Graft Dysfunction After Heart Transplantation

Potential benefits of melatonin in organ transplantation: a review

Contact Info

Product

Resources

About